Despite the availability of KRAS-targeted therapies in later lines, the decision-making for first-line treatment in KRAS-mutant NSCLC is still primarily guided by PD-L1 expression and clinical factors, rather than KRAS mutation status itself. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.